FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kwan Rudolf		 2. Issuer Name and Ticker or Trading Symbol

Athenex, Inc. [ ATNX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Chief Medical Officer
(Last)          (First)          (Middle)

C/O ATHENEX, INC.,, 1001 MAIN STREET, SUITE 600		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/10/2023
(Street)

BUFFALO, NY 14203
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/10/2023  A  2526 A$1.94 (1)34916 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $91.00           5/13/2018 5/13/2023 Common Stock 2400  2400 D  
Stock Option (Right to Buy) $91.00           2/12/2018 2/12/2024 Common Stock 6000  6000 D  
Stock Option (Right to Buy) $91.00           6/12/2017 6/12/2024 Common Stock 2400  2400 D  
Stock Option (Right to Buy) $110.00           12/16/2018 12/16/2024 Common Stock 10000  10000 D  
Stock Option (Right to Buy) $150.00           5/22/2019 5/22/2025 Common Stock 6000  6000 D  
Stock Option (Right to Buy) $220.00           6/13/2020 6/13/2027 Common Stock 7000  7000 D  
Stock Option (Right to Buy) $346.00           3/27/2022 3/27/2028 Common Stock 6000  6000 D  
Stock Option (Right to Buy) $263.40           2/28/2023 2/28/2029 Common Stock 6000  6000 D  
Stock Option (Right to Buy) $249.00            (2)6/5/2030 Common Stock 7000  7000 D  
Stock Option (Right to Buy) $76.00            (3)8/3/2031 Common Stock 3500  3500 D  
Restricted Stock Units  (4)           (5) (5)Common Stock 2625  2625 D  
Stock Option (Right to Buy) $13.31            (6)7/20/2032 Common Stock 3750  3750 D  
Explanation of Responses:
(1) Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
(2) This option vests in four equal annual installments beginning on June 5, 2021.
(3) The option vests in four equal annual installments beginning on August 3, 2022.
(4) Each restricted stock unit represents a contingent right to receive one share of stock.
(5) The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
(6) This option vests in four equal annual installments beginning on July 20, 2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Kwan Rudolf
C/O ATHENEX, INC.,
1001 MAIN STREET, SUITE 600
BUFFALO, NY 14203

EVP, Chief Medical Officer
Signatures
/s/ Steven Adams, Attorney-in-Fact3/13/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Athenex Charts.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Athenex Charts.